论文部分内容阅读
资料来源:FDA网站发布时间:2012.1.31验证性实验表明伊马替尼具有显著的有效延长患者的生存期,药品应给予定期审批。美国食品药品管理局(FDA)今天允许定期审批伊马替尼在成人患者CD117阳性的胃肠道间质瘤(GIST)手术切除后的使用。今天的行为也凸显了,当药物服用为36个月而不是标准的12个月治疗时,患者整体的生存期延长了。
Source: FDA Published: 2012.1.31 Confirmatory experiments showed that imatinib significantly prolongs the survival of patients and should be regularly approved. The U.S. Food and Drug Administration (FDA) today approved the routine approval of imatinib for its use following surgical resection of adult patients with CD117-positive gastrointestinal stromal tumors (GIST). Today’s behavior also highlights the overall survival of patients as the drug is taken for 36 months instead of the standard 12-month treatment.